Oral Factor D Inhibition Falls Short in AChR-Positive Generalized Myasthenia Gravis: What the Vemircopan Phase 2 Trial Means for Complement-Targeted Therapy
In this phase 2, double-blind randomized clinical trial, oral vemircopan, a selective factor D inhibitor, did not outperform placebo in acetylcholine receptor antibody-positive generalized myasthenia gravis.
The primary responder endpoint was numerically similar across groups: 64% with placebo, 57% with vemircopan 180 mg twice daily, and 57% with vemircopan 120 mg twice daily.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
